Penny Stock Pick - MZT

Better Cancer Test The penny stock company on the spotlight today is Matritech Inc.(MZT), the Newton, MA based biotechnology company focusing on cancer diagnostic technologies. The shares have been flying for the second consecutive session, up 22.81% or 26 cents to $1.4 per share today, after the company announced that its cancer detection test uncovered cnacers that standard tests didn't detect. The positive news sparked the surge as the stock went from 89 cents on April 6 to $1.4 today, rising more than 50% within a week. Let's take a closer look at the company to see if the stock is worth buying.

Technical
The technical chart shows the stock has entered into bull market as the stock is on top of 50 day and 200 day moving average with 50 day moving average in mid February crossed on top over 200 day moving average to form Golden Cross, a very bullish sign. Other technical indicators such as KD line and MACD indicate buy as K line is on top over D line and MACD is on top over the signal line. The ROC signal, however is at overbought level so may have the risk of correction.

Insider
From the recent acquisitions and purchases of shares from top executives such as vice president, secretary, chairman, CFO, we should be pretty confident that the stock should be doing well from now on. Additional purchse of 849,390 shares from institutions is just another plus.

Financial
The income statement also looks promising as the company has continuous strong revenue growth at least for the past three years. Another positive sign is net loss which had been reduced from 11 million in 2004 to 7.8 million last year. However from the balance sheet the cash has reduced to 1.8 million last December so financing may be needed.

Penny Stock Score (1~5) 5 is highest
1. Market Potential(Cancer Test): 4
2. News: 5
3. Technical: 4
4. Insider: 5
5. Financial: 4
Recommendation: Strong Buy